Bernstein upgraded BioMarin to Market Perform from Underperform with an unchanged price target of $82. The firm’s short thesis was that Roctavian numbers needed to come down, and this has largely played out, the analyst tells investors in a research note. Bernstein believes there is still some downside to Roctavian consensus, but says the buy-side is largely in the same place as it is, making consensus sales estimates “now reasonable.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin reports FDA approves expanded indication for Voxzogo
- BioMarin initiated with a Market Perform at Raymond James
- BioMarin receives FDA orphan designation for HCM treatment
- BioMarin to present data showing LT benefit of Voxzogo on children’s growth
- Micron upgraded, PayPal downgraded: Wall Street’s top analyst calls
